[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525288":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":33,"locations":42,"responsibleParty":62,"collaborators":66,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":97,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":21,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":21,"overallStatus":44,"whyStopped":21,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Oslo University Hospital","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"treatment according to genetic alterations","EXPERIMENTAL",[12,13,14],"Drug: Imatinib","Drug: Trametinib","Drug: Dabrafenib",[16,22,26],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Imatinib","imatinib treatment based on molecular alterations",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Trametinib","According to biomarkers",[9],{"type":17,"name":27,"description":24,"armGroupLabels":28,"otherNames":21},"Dabrafenib",[9],[30],{"name":31,"affiliation":5,"role":32},"Sigbjørn Smeland, MD PhD","STUDY_CHAIR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":21,"email":38},"Åslaug Helland, MD PhD","CONTACT","+4795940863","ahelland@medisin.uio.no",{"name":40,"role":36,"phone":21,"phoneExt":21,"email":41},"Kathinka Slørdahl, MD PhD","katslo@ous-hf.no",[43],{"facility":5,"status":44,"city":45,"state":21,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Oslo","0310","Norway","NO",{"type":50,"coordinates":51},"Point",[52,53],10.74609,59.91273,{"lat":53,"lon":52},[56,59],{"name":57,"role":36,"phone":21,"phoneExt":21,"email":58},"Åsa Öjlert, MD PhD","aasojl@ous-hf.no",{"name":60,"role":36,"phone":21,"phoneExt":21,"email":61},"Katarina Puco, MD","katpuc@ous-hf.no",{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"PRINCIPAL_INVESTIGATOR","Åslaug Helland","Professor",[67,70,72,75,77,79,81,83,85,87,89,91,93],{"name":68,"class":69},"Helse Stavanger HF","OTHER_GOV",{"name":71,"class":6},"University Hospital of North Norway",{"name":73,"class":74},"StOlavs Hospital","UNKNOWN",{"name":76,"class":6},"Nordlandssykehuset HF",{"name":78,"class":6},"Helse Nord-Trøndelag HF",{"name":80,"class":69},"Sorlandet Hospital HF",{"name":82,"class":6},"Møre og Romsdal Hospital Trust",{"name":84,"class":6},"The Hospital of Vestfold",{"name":86,"class":6},"Helse Fonna",{"name":88,"class":6},"Haukeland University Hospital",{"name":90,"class":6},"Sykehuset Ostfold",{"name":92,"class":6},"Helse Forde",{"name":94,"class":6},"Sykehuset Innlandet HF","100525288","phase-2-precision-cancer-therapy-in-rare-cancers-100525288",false,"NCT06119789","Precision Cancer Therapy in Rare Cancers","The MATRIX Clinical Studies of Precision Cancer Therapy for Rare Cancers","MATRIX-Rare","Inclusion Criteria:\n\n* ECOG 0-2,\n* identified biomarker,\n* reasonable biochemistry\n\nExclusion Criteria:\n\n* ECOG 3-5\n* serious other diseases","ALL","16 Years","99 Years",{"count":107,"type":108},96,"ESTIMATED","INTERVENTIONAL",[111],"PHASE2","Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers.\n\nIn this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.",[114],"Rare Malignant Neoplasm","2025-03-23",{"date":117,"type":118},"2025-03-26","ACTUAL",{"date":120,"type":118},"2025-03-20",{"date":122,"type":108},"2036-08-01",{"name":5,"class":6},1]